Heart Failure with Preserved Ejection Fraction Viewed as a Systemic Inflammatory-Metabolic Condition: Insights from the Cardio-Hepato-Pancreatic Axis - Scorecard - MDSpire
Advertisement
Heart Failure with Preserved Ejection Fraction Viewed as a Systemic Inflammatory-Metabolic Condition: Insights from the Cardio-Hepato-Pancreatic Axis
Clinical Scorecard: Heart Failure with Preserved Ejection Fraction Viewed as a Systemic Inflammatory-Metabolic Condition: Insights from the Cardio-Hepato-Pancreatic Axis
At a Glance
Category
Detail
Condition
Key Mechanisms
Systemic inflammation and metabolic dysfunction affecting the cardiovascular system, supported by recent studies.
Target Population
Care Setting
Key Highlights
Add references to studies supporting the efficacy of SGLT2 inhibitors and GLP-1 receptor agonists.
Guideline-Based Recommendations
Diagnosis
Management
Focus on interventions that target congestion, inflammation, and metabolic dysregulation, with specific examples.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with HFpEF, particularly those with comorbidities like obesity and diabetes.
SGLT2 inhibitors and GLP-1 receptor agonists may provide systemic benefits beyond heart function.
Clinical Best Practices
Provide specific examples of how each specialty (cardiology, hepatology, gastroenterology) contributes to patient care.
